Skip to main content

Table 2 Adjusted hazard ratios (95%CI) for overall survival and breast cancer-specific survival by tumor CYP27A1 expression in MDCS cohort

From: CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients

 

Model 0a

Model 1b

Model 2c

Cases

Events

CYP27A1 high vs low HR (95%CI)

Cases

Events

CYP27A1 high vs low HR (95%CI)

Cases

Events

CYP27A1 high vs low HR (95%CI)

Follow-up period ≤ 5 years

Overall survival

  All

645

76

0.97 (0.56–1.69)

569

69

0.86 (0.47–1.57)

514

63

0.68 (0.35–1.31)

  

P = 0.92

  

P = 0.63

  

P = 0.25

  ER+

522

52

1.05 (0.53–1.03)

498

51

1.09 (0.54–2.19)

448

47

0.91 (0.43–1.93)

  

P = 0.87

  

P = 0.81

  

P = 0.81

  ER+ and age ≥ 55 yrs

472

51

1.10 (0.55–2.21)

450

50

1.11 (0.55–2.23)

400

46

0.97 (0.46–2.05)

  

P = 0.78

  

P = 0.76

  

P = 0.93

Breast cancer-specific survival

  All

645

46

0.92 (0.44–1.93)

569

41

0.67 (0.30–1.51)

514

38

0.54 (0.22–1.31)

  

P = 0.83

  

P = 0.34

  

P = 0.17

  ER+

522

26

0.61 (0.18–2.03)

498

26

0.63 (0.19–2.10)

448

25

0.57 (0.16–1.95)

  

P = 0.42

  

P = 0.45

  

P = 0.37

  ER+ and age ≥ 55 yrs

472

25

0.64 (0.19–2.16)

450

25

0.64 (0.19–2.14)

400

24

0.63 (0.18–2.15)

  

P = 0.47

  

P = 0.47

  

P = 0.46

Follow-up period > 5 years

Overall survival

  All

567

145

1.66 (1.14–2.43)

498

129

1.89 (1.25–2.85)

449

123

1.93 (1.26–2.97)

  

P = 0.009

  

P = 0.003

  

P = 0.003

  ER+

468

122

1.76 (1.14–2.71)

445

117

1.79 (1.16–2.77)

399

112

1.78 (1.13–2.80)

  

P = 0.01

  

P = 0.009

  

P = 0.01

  ER+ and age ≥ 55 yrs

419

112

1.85 (1.18–2.91)

398

107

1.91 (1.22–3.03)

352

102

1.99 (1.24–3.21)

  

P = 0.007

  

P = 0.005

  

P = 0.004

Breast cancer-specific survival

  All

567

66

2.18 (1.28–3.73)

498

60

2.25 (1.26–4.01)

449

58

2.33 (1.28–4.23)

  

P = 0.004

  

P = 0.006

  

P = 0.006

  ER+

468

54

2.22 (1.19–4.12)

445

54

2.18 (1.18–4.03)

399

52

2.26 (1.20–4.27)

  

P = 0.01

  

P = 0.01

  

P = 0.01

  ER+ and age ≥ 55 yrs

419

46

2.56 (1.33–4.91)

398

46

2.57 (1.34–4.94)

352

44

2.78 (1.41–5.51)

  

P = 0.005

  

P = 0.005

  

P = 0.003

  1. HR hazard ratio, CI confidence interval, ER+ estrogen receptor positive
  2. aModel 0: adjusted for FFPE block storage duration
  3. bModel 1: adjusted for age at diagnosis, tumor size, lymph node involvement, ER expression, tumor histological grade and FFPE block storage duration
  4. cModel 2: Model 1 + adjusted for local (radiotherapy) and systemic (endocrine and chemotherapy) treatments